Publicaties
C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting Vrije Universiteit Brussel
The objective of this study was to evaluate the utility of serum C-reactive protein (CRP) as biomarker for the early diagnosis of immune-related adverse events (irAEs) in melanoma patients treated with immune checkpoint inhibitors (ICIs) in the adjuvant setting, and its potential correlation with relapse-free survival (RFS). Prospectively collected data from 72 melanoma patients treated with adjuvant ICIs were pooled. CRP values at diagnosis ...
Immune checkpoint inhibitors and type 1 diabetes mellitus Vrije Universiteit Brussel
Objective: To better define the rare adverse event (AE) of diabetes mellitus associated with immune checkpoint inhibitors (ICIs). Design and methods: We report the case of a lung cancer patient with diabetic ketoacidosis (DKA) and autoimmune thyroiditis during pembrolizumab treatment. We provide a systematic review of all published cases (PubMed/Web of Science/Cochrane, through November 2018) of autoimmune diabetes mellitus related to ...
Health-related quality of life, psychological outcome and neurocognitive function in metastatic melanoma survivors treated with immune checkpoint inhibitors Vrije Universiteit Brussel
Managing viral hepatitis in cancer patients under immune checkpoint inhibitors : should we take the risk? Universiteit Gent
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review KU Leuven
What is the place of the combinations for immunotherapy with chemotherapy or with other immune checkpoint inhibitors? Vrije Universiteit Brussel
Immune checkpoint blockade by the use of anti-PD(L)1 or anti-CTLA4 antibodies can induce long lasting disease response and maybe cure in a lot of advanced cancer patients. This ongoing immunotherapy revolution has given new hope to cancer patients and oncologists. However, still the majority of cancer patients do not respond to immune checkpoint blockade and novel therapeutical possibilities are being tested in several clinical trials. One of ...